2012 Volume 20 Issue 1 Pages 17-23
Background: While surgery remains the sole mainstay of any curative treatment for gastric cancer, the relapse rate is high and survival remains low even after surgical resection with curative intent.
Methods: Based on biochemical modulation theory, this trial was assigned for gastric cancer patients as post operative adjuvant setting with at least 4 cycles of either UFT (UF group) or 5-FU plus low dose cisplatin (CF) and UFT (CD group). The planned 4 cycles of CF treatment was received by 95% of patients in the CD group. One year of UFT was received by 93 (99%) and 91 (97%) of the patients in the groups administered UFT and cisplatin/5FU+UFT, respectively.
Results: The result suggests better 5 year survival rate in the combination treatment group, with a reduction in risk of 13%. 5 year DFS was also showed benefit of combination therapy over UFT alone, with a reduction in risk of 15%.
Conclusion: These findings from our phase III randomized trial suggest that low dose cisplatin+5-FU followed by UFT may hold promise as a treatment for curatively resected locally advanced gastric cancer patients.